

PHAXIAM Therapeutics announces judicial liquidation and delisting

Lyon (France) – June 12, 2025 at 6:00pm CEST – PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (*liquidation judiciaire*) of the Company on June 11, 2025.

As part of the judicial receivership proceedings (*redressement judiciaire*), two offers were submitted but were unable to result in the acquisition of PHAXIAM's assets. The Lyon Commercial Court has appointed Maître Pierre Martin as liquidator.

Following this decision, PHAXIAM Therapeutics will request the delisting of its shares from Euronext, as previously announced. PHAXIAM reiterates that no reimbursement to shareholders can be made.

Despite the efforts undertaken by the Company and its management to extend its financing horizon and maintain its operations, extremely challenging market conditions—particularly for small-cap listed biotech companies—did not allow for the implementation of a viable refinancing solution, leading the Company to file for receivership in early March 2025.

Since 2017, PHAXIAM has provided more than 140 patients with phage-based treatments produced under pharmaceutical-grade standards, within a compassionate use framework. The Company sincerely hopes that these patients will continue to receive appropriate medical care and support despite the cessation of its activities.

PHAXIAM would like to express its deep gratitude to all its stakeholders – including employees, partners, healthcare professionals, and shareholders – for their dedication and support throughout its journey.

About PHAXIAM Therapeutics

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit www.phaxiam.com

Contacts

PHAXIAM
Thibaut du Fayet
 CEO
 +33 4 78 74 44 38
investors@phaxiam.com

NewCap
Mathilde Bohin / Dušan Orešanský
 Investor Relations
Arthur Rouillé
 Media Relations
 +33 1 44 71 94 94
phaxiam@newcap.eu